Abstract
The cell source for hematopoietic cell transplantation (HCT) can be autologous, related allogeneic, or unrelated allogeneic. Autologous cell therapy (CT) and related allogeneic CD34+ cell products are often collected and processed in the same facility as the transplant center. This is not the case, however, for unrelated donor cord blood, peripheral blood, or bone marrow transplantation that are facilitated by registries—such as the National Marrow Donor Program (NMDP) and the World Marrow Donor Association (WMDA)—that are involved in the public exchange of these allogeneic CT products worldwide. Non-cryopreserved and cryopreserved allogeneic CT products are, therefore, frequently transferred on public roads as well as on aircrafts to geographically distant facilities. Since the infusion is usually scheduled within 48–72 h after collection (for non-cryopreserved CT products) or after receipt at the transplant center (for cryopreserved CT products), this process mandates complex coordination by highly trained personnel. The process of transferring CT products is tightly regulated by the Food and Drug Administration (FDA), Department of Transportation (DOT), International Air Transport Association (IATA), International Civil Aviation Organization (ICAO), AABB (formerly known as the American Association of Blood Banks), and Foundation for the Accreditation of Cellular Therapy (FACT). The regulations that must be followed depend on the hazardous material classification of the biological and cryogenic substances in the transfer container. The requirements for continuous temperature monitoring and the procedures for packaging, labeling, and documentation are all designed to maintain the integrity of the CT product while protecting the health and safety of personnel involved in the transfer process. It is essential to clearly document the chain of custody as the CT product is transferred from the cosigner (transfer facility) to the consignee (receiving facility) via the courier. Upon receipt, trained personnel at the receiving facility should promptly follow the instructions for opening the container and inspecting the CT product as well as make a decision to accept, reject, or quarantine the CT product.
Similar content being viewed by others
References
AABB (2015) Standards for cellular therapy services, 7th edn. AABB Publications, Bethesda, MD
Antonenas V, Garvin F, Webb M et al (2006) Fresh PBSC harvests, but not BM, show temperature-related loss of CD34 viability during storage and transport. Cytotherapy 8:158–165
Code of Federal Regulations (n.d.) Title 49 CFR—Transportation—Parts 171–180—hazardous materials regulations
Donaldson C, Armitage WJ, Denning-Kendall PA et al (1996) Optimal cryopreservation of human umbilical cord blood. Bone Marrow Transplant 18:725–731
International Air Transport Association (IATA) (n.d.). Dangerous Goods Regulations 2.3A. Packing instructions 650
International Civil Aviation Organization (ICAO) (n.d.) Technical instructions for the safe transport of dangerous goods by air. Packing instructions 202
Leemhuis T, Padley D, Keever-Taylor C et al (2014) Essential requirements for setting up a stem cell processing laboratory. Bone Marrow Transplant 49:1098–1105
Olson WC, Smolkin ME, Farris EM et al (2011) Shipping blood to a central laboratory in multicenter clinical trials: effect of ambient temperature on specimen temperature, and effects of temperature on mononuclear cell yield, viability, and immunologic function. J Transl Med 9:26
The Foundation for the Accreditation of Cellular Therapy (FACT) and the Joint Accreditation Committee ISCT and EBMT (2015) International standards for hematopoietic cellular therapy collection, processing, and administration, 6th edn. http://www.jacie.org/standards/6th-edition-2015. Accessed 10 Jan 2017
Wada RK, Bradford A, Moogk M et al (2004) Cord blood units collected at a remote site: a collaborative endeavor to collect umbilical cord blood through the Hawaii Cord Blood Bank and store the units at the Puget Sound Blood Center. Transfusion 44:111–118
Yang H, Acker JP, Hannon J et al (2011) Damage and protection of UC blood cells during cryopreservation. Cytotherapy 3:377–386
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG
About this chapter
Cite this chapter
Lin, D.MH., Gibbons, J.M., Gallacher, A.T., Haley, R. (2018). Hematopoietic Graft Handling During Transportation. In: Schwartz, J., Shaz, B. (eds) Best Practices in Processing and Storage for Hematopoietic Cell Transplantation . Advances and Controversies in Hematopoietic Transplantation and Cell Therapy. Springer, Cham. https://doi.org/10.1007/978-3-319-58949-7_12
Download citation
DOI: https://doi.org/10.1007/978-3-319-58949-7_12
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-58948-0
Online ISBN: 978-3-319-58949-7
eBook Packages: MedicineMedicine (R0)